|
Name |
25-hydroxyophiobolin I
|
| Molecular Formula | C25H36O4 | |
| IUPAC Name* |
(1'R,2S,3S,3'S,5R,7'R,8'E,11'R)-8'-(hydroxymethyl)-5-[(Z)-3-hydroxy-2-methylprop-1-enyl]-1',3,4'-trimethylspiro[oxolane-2,12'-tricyclo[9.3.0.03,7]tetradeca-4,8-diene]-6'-one
|
|
| SMILES |
C[C@H]1C[C@@H](O[C@@]12CC[C@]3([C@H]2C/C=C(\[C@H]4[C@H](C3)C(=CC4=O)C)/CO)C)/C=C(/C)\CO
|
|
| InChI |
InChI=1S/C25H36O4/c1-15(13-26)9-19-11-17(3)25(29-19)8-7-24(4)12-20-16(2)10-21(28)23(20)18(14-27)5-6-22(24)25/h5,9-10,17,19-20,22-23,26-27H,6-8,11-14H2,1-4H3/b15-9-,18-5-/t17-,19-,20+,22+,23-,24+,25-/m0/s1
|
|
| InChIKey |
AQGWDSZHWQWPPZ-LYDXBNIFSA-N
|
|
| Synonyms |
25-hydroxyophiobolin I
|
|
| CAS | NA | |
| PubChem CID | 146684977 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 400.5 | ALogp: | 2.7 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 66.8 | Aromatic Rings: | 4 |
| Heavy Atoms: | 29 | QED Weighted: | 0.679 |
| Caco-2 Permeability: | -4.703 | MDCK Permeability: | 0.00001690 |
| Pgp-inhibitor: | 0.254 | Pgp-substrate: | 0.036 |
| Human Intestinal Absorption (HIA): | 0.173 | 20% Bioavailability (F20%): | 0.794 |
| 30% Bioavailability (F30%): | 0.074 |
| Blood-Brain-Barrier Penetration (BBB): | 0.852 | Plasma Protein Binding (PPB): | 64.34% |
| Volume Distribution (VD): | 1.99 | Fu: | 20.57% |
| CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.395 |
| CYP2C19-inhibitor: | 0.023 | CYP2C19-substrate: | 0.652 |
| CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.055 |
| CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.22 |
| CYP3A4-inhibitor: | 0.93 | CYP3A4-substrate: | 0.482 |
| Clearance (CL): | 10.449 | Half-life (T1/2): | 0.565 |
| hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.663 |
| Drug-inuced Liver Injury (DILI): | 0.431 | AMES Toxicity: | 0.018 |
| Rat Oral Acute Toxicity: | 0.482 | Maximum Recommended Daily Dose: | 0.889 |
| Skin Sensitization: | 0.893 | Carcinogencity: | 0.285 |
| Eye Corrosion: | 0.145 | Eye Irritation: | 0.115 |
| Respiratory Toxicity: | 0.966 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002271 | ![]() |
0.847 | D0E9KA | ![]() |
0.276 | ||
| ENC001559 | ![]() |
0.486 | D06AEO | ![]() |
0.269 | ||
| ENC003209 | ![]() |
0.468 | D08PIQ | ![]() |
0.264 | ||
| ENC005803 | ![]() |
0.467 | D0Y2YP | ![]() |
0.262 | ||
| ENC005044 | ![]() |
0.458 | D02JNM | ![]() |
0.256 | ||
| ENC005045 | ![]() |
0.432 | D04SFH | ![]() |
0.254 | ||
| ENC005046 | ![]() |
0.418 | D0I5DS | ![]() |
0.254 | ||
| ENC002982 | ![]() |
0.365 | D0CZ1Q | ![]() |
0.254 | ||
| ENC003251 | ![]() |
0.351 | D0C8HR | ![]() |
0.252 | ||
| ENC002981 | ![]() |
0.339 | D0IT2G | ![]() |
0.250 | ||